These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

229 related articles for article (PubMed ID: 28623515)

  • 21. Second-line treatment options for patients with metastatic pancreatic ductal adenocarcinoma: A systematic literature review.
    Dayyani F; Macarulla T; Johnson A; Wainberg ZA
    Cancer Treat Rev; 2023 Feb; 113():102502. PubMed ID: 36641880
    [TBL] [Abstract][Full Text] [Related]  

  • 22. State of the art and future directions of pancreatic ductal adenocarcinoma therapy.
    Neuzillet C; Tijeras-Raballand A; Bourget P; Cros J; Couvelard A; Sauvanet A; Vullierme MP; Tournigand C; Hammel P
    Pharmacol Ther; 2015 Nov; 155():80-104. PubMed ID: 26299994
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Challenges and future directions in therapeutics for pancreatic ductal adenocarcinoma.
    Al Haddad AH; Adrian TE
    Expert Opin Investig Drugs; 2014 Nov; 23(11):1499-515. PubMed ID: 25078674
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Systemic Chemotherapy for Advanced Rare Pancreatic Histotype Tumors: A Retrospective Multicenter Analysis.
    Brunetti O; Aprile G; Marchetti P; Vasile E; Casadei Gardini A; Scartozzi M; Barni S; Delfanti S; De Vita F; Di Costanzo F; Milella M; Cella CA; Berardi R; Cataldo I; Scarpa A; Basile D; Mazzuca F; Graziano G; Argentiero A; Santini D; Reni M; Cascinu S; Silvestris N
    Pancreas; 2018 Jul; 47(6):759-771. PubMed ID: 29771769
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Phase I study assessing the feasibility of the triple combination chemotherapy of SOXIRI (S-1/oxaliplatin/irinotecan) in patients with unresectable pancreatic ductal adenocarcinoma.
    Yanagimoto H; Satoi S; Sho M; Akahori T; Yamamoto T; Hirooka S; Yamaki S; Kotsuka M; Ryota H; Kinoshita S; Nishiwada S; Nagai M; Ikeda N; Tsuta K; Nakajima Y; Kon M
    Cancer Chemother Pharmacol; 2016 Jan; 77(1):35-41. PubMed ID: 26645403
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Cyclophosphamide maintenance to extend combination chemotherapy-free interval in metastatic pancreatic ductal adenocarcinoma.
    Reni M; Peretti U; Macchini M; Orsi G; Militello A; Briccolani A; Falconi M; Cascinu S
    Dig Liver Dis; 2024 Mar; 56(3):509-513. PubMed ID: 37586911
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Postoperative Serum Albumin Level is a Marker of Incomplete Adjuvant Chemotherapy in Patients with Pancreatic Ductal Adenocarcinoma.
    Matsumoto I; Tanaka M; Shirakawa S; Shinzeki M; Toyama H; Asari S; Goto T; Yamashita H; Ishida J; Ajiki T; Fukumoto T; Shimokawa M; Ku Y
    Ann Surg Oncol; 2015 Jul; 22(7):2408-15. PubMed ID: 25487967
    [TBL] [Abstract][Full Text] [Related]  

  • 28. The Addition of Postoperative Chemotherapy is Associated with Improved Survival in Patients with Pancreatic Cancer Treated with Preoperative Therapy.
    Roland CL; Katz MH; Tzeng CW; Lin H; Varadhachary GR; Shroff R; Javle M; Fogelman D; Wolff RA; Vauthey JN; Crane CH; Lee JE; Fleming JB
    Ann Surg Oncol; 2015 Dec; 22 Suppl 3(Suppl 3):S1221-8. PubMed ID: 26350371
    [TBL] [Abstract][Full Text] [Related]  

  • 29. A gut response: Modulating chemotherapy efficacy with microbial metabolites.
    Bauer KC; Greten TF
    Immunity; 2023 Apr; 56(4):750-752. PubMed ID: 37044066
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Combination of Anti-miRNAs Oligonucleotides with Low Amounts of Chemotherapeutic Agents for Pancreatic Cancer Therapy.
    Passadouro M; Faneca H
    Methods Mol Biol; 2018; 1699():135-154. PubMed ID: 29086375
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Pharmacotherapeutic strategies for treating pancreatic cancer: advances and challenges.
    Diab M; Azmi A; Mohammad R; Philip PA
    Expert Opin Pharmacother; 2019 Apr; 20(5):535-546. PubMed ID: 30592647
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Prognosis following surgical bypass compared with laparotomy alone in unresectable pancreatic adenocarcinoma.
    Insulander J; Sanjeevi S; Haghighi M; Ivanics T; Analatos A; Lundell L; Del Chiaro M; Andrén-Sandberg Å; Ansorge C
    Br J Surg; 2016 Aug; 103(9):1200-8. PubMed ID: 27250937
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Advanced pancreatic cancer - how to choose an adequate treatment option.
    Korkeila EA
    World J Gastroenterol; 2015 Oct; 21(38):10709-13. PubMed ID: 26478662
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Biomarker-driven and molecularly targeted therapies for pancreatic adenocarcinoma.
    Zhen DB; Coveler A; Zanon S; Reni M; Chiorean EG
    Semin Oncol; 2018 Jun; 45(3):107-115. PubMed ID: 30391013
    [TBL] [Abstract][Full Text] [Related]  

  • 35. SOURCE-PANC: A Prediction Model for Patients With Metastatic Pancreatic Ductal Adenocarcinoma Based on Nationwide Population-Based Data.
    van den Boorn HG; Dijksterhuis WPM; van der Geest LGM; de Vos-Geelen J; Besselink MG; Wilmink JW; van Oijen MGH; van Laarhoven HWM
    J Natl Compr Canc Netw; 2021 Jul; 19(9):1045-1053. PubMed ID: 34293719
    [TBL] [Abstract][Full Text] [Related]  

  • 36. ASO Author Reflections: Systemic Immune-Inflammation Index (SII) as a Biomarker of Response to Neoadjuvant Therapy in Patients with Pancreatic Adenocarcinoma.
    Murthy P; Boone BA
    Ann Surg Oncol; 2020 Mar; 27(3):907-908. PubMed ID: 31823171
    [No Abstract]   [Full Text] [Related]  

  • 37. Impact of Nab-Paclitaxel-based Second-line Chemotherapy in Metastatic Pancreatic Cancer.
    Dadi N; Stanley M; Shahda S; O'Neil BH; Sehdev A
    Anticancer Res; 2017 Oct; 37(10):5533-5539. PubMed ID: 28982867
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Safety and efficacy of neoadjuvant FOLFIRINOX treatment in a series of patients with borderline resectable pancreatic ductal adenocarcinoma.
    Tinchon C; Hubmann E; Pichler A; Keil F; Pichler M; Rabl H; Uggowitzer M; Jilek K; Leitner G; Bauernhofer T
    Acta Oncol; 2013 Aug; 52(6):1231-3. PubMed ID: 23445338
    [No Abstract]   [Full Text] [Related]  

  • 39. Case Report: Maintenance Nivolumab in Complete Responder After Multimodality Therapy in Metastatic Pancreatic Adenocarcinoma.
    Yang SH; Lee JC; Chen BB; Kuo SH; Hsu C; Bai LY
    Front Immunol; 2022; 13():870406. PubMed ID: 35572526
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Chemotherapy: NAPOLI-1: winning scoop for metastatic pancreatic cancer.
    Hutchinson L
    Nat Rev Clin Oncol; 2016 Jan; 13(1):2-3. PubMed ID: 26667974
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 12.